KR970705997A - N-4-[2-1234--67--2--]--910--5--9--4- gf120918a parenteral pharmaceutical compositions containing gf120918a - Google Patents

N-4-[2-1234--67--2--]--910--5--9--4- gf120918a parenteral pharmaceutical compositions containing gf120918a

Info

Publication number
KR970705997A
KR970705997A KR1019970702223A KR19970702223A KR970705997A KR 970705997 A KR970705997 A KR 970705997A KR 1019970702223 A KR1019970702223 A KR 1019970702223A KR 19970702223 A KR19970702223 A KR 19970702223A KR 970705997 A KR970705997 A KR 970705997A
Authority
KR
South Korea
Prior art keywords
pharmaceutical composition
effective amount
group
safe
composition
Prior art date
Application number
KR1019970702223A
Other languages
Korean (ko)
Inventor
웨이-킨 통
믹키 리 웰즈
Original Assignee
그래함 브레레톤
글락소 웰컴 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 그래함 브레레톤, 글락소 웰컴 인크. filed Critical 그래함 브레레톤
Publication of KR970705997A publication Critical patent/KR970705997A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

a) 안전한 치료 유효량의 N-{4-[2-(1,2,3,4-테트라히드로-6,7-디메톡시-2-이소퀴놀리닐)-에틸]-페닐}-9,10-디히드로-5-메톡시-9-옥소-4-아크리딘 카르복사미드 및 이것의 생리적으로 허용되는 염 및 용매화물; b) 안전한 유효량의 계면활성제; c) 완충제; 및 d) 제약상 허용되는 담체를 포함하는, 주사 또는 주입시의 침전을 방지하거나 최소화하는 제약 조성물.a) administering a safe therapeutically effective amount of N- {4- [2- (1,2,3,4-tetrahydro-6,7-dimethoxy-2-isoquinolinyl) -ethyl] -phenyl} -Dihydro-5-methoxy-9-oxo-4-acridinecarboxamide and physiologically acceptable salts and solvates thereof; b) a safe effective amount of a surfactant; c) buffering agents; And d) a pharmaceutically acceptable carrier. A pharmaceutical composition for preventing or minimizing precipitation upon injection or infusion.

Description

N-{4-[2-(1,2,3,4-테트라히드로-6,7-디메톡시-2-이소퀴놀리닐)-에틸]-페닐}-9,10-디히드로-5-매톡시-9-옥소-4-아크리딘 카르복사미드 화합물(GF120918A)을 포함하는 비경구 제약 조성물(PARENTERAL PHARMACEUTICAL COMPOSITIONS CONTAINING GF120918A)N- {4- [2- (1,2,3,4-tetrahydro-6,7-dimethoxy-2-isoquinolinyl) -ethyl] -phenyl} -9,10-dihydro- (PARENTERAL PHARMACEUTICAL COMPOSITIONS CONTAINING GF120918A) comprising a methoxy-9-oxo-4-acridine carboxamide compound (GF120918A)

본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음Since this is a trivial issue, I did not include the contents of the text.

Claims (20)

a) 안전한 유효량의 N-{4-[2-(1,2,3,4-테트라히드로-6,7-디메톡시-2-이소퀴놀리닐)-에틸]-페닐}-9,10-디히드로-5-매톡시-9-옥소-4-아크리딘 카르복사미드 및 이것의 생리적으로 허용되는 염 및 용매화물; b) 안전한 유효량의 계면활성제; c) 완충제; 및 d) 제약상 허용되는 담체 및 회석제를 포함하는, 비경구 투여에 있어서 조성물의 활성 성분의 침전을 방지하거나 최소화하는 제약 조성물.a) a safe effective amount of N- {4- [2- (1,2,3,4-tetrahydro-6,7-dimethoxy-2- isoquinolinyl) -ethyl] -phenyl} Dihydro-5-methoxy-9-oxo-4-acridine carboxamide and physiologically acceptable salts and solvates thereof; b) a safe effective amount of a surfactant; c) buffering agents; And d) a pharmaceutically acceptable carrier and a chelating agent to prevent or minimize precipitation of the active ingredient of the composition in parenteral administration. 제1항에 있어서, pH가 약 1 내지 약 5인 제약 조성물.3. The pharmaceutical composition of claim 1, wherein the pH is from about 1 to about 5. & 제2항에 있어서 N-{4-[2-(1,2,3,4-테트라히드로-6,7-디메톡시-2-이소퀴놀리닐)-에틸]-페닐}-9,10-디히드로-5-매톡시-9-옥소-4-아크리딘 카르복사미드 또는 이것의 생리적으로 허용되는 염 및 용매화물이 약 1㎎ 내지 약 10g인 제약 조성물.6. The compound according to claim 2, which is N- {4- [2- (1,2,3,4-tetrahydro-6,7-dimethoxy-2-isoquinolinyl) -ethyl] -phenyl} Dihydro-5-methoxy-9-oxo-4-acridine carboxamide or physiologically acceptable salts and solvates thereof is about 1 mg to about 10 g. 제3항에 있어서, 제3항에 있어서, 계면 활성제가 폴리에틸렌 글리콜 660히드록시테아레이트, 폴리옥시에틸렌 피마자유 유도체, 폴록사머, 폴리옥시에틸렌 알킬 에테르, 폴리옥시 에틸렌 소르비탄 지방산 에스테르, 폴리에틸렌 글리콜, 프로필렌 글리콜, 에탄올 및 글리세린으로 이루어진 군으로부터 선택된 것인 제약 조성물.4. The composition of claim 3, wherein the surfactant is selected from the group consisting of polyethylene glycol 660 hydroxytearate, polyoxyethylene castor oil derivative, poloxamer, polyoxyethylene alkyl ether, polyoxyethylene sorbitan fatty acid ester, polyethylene glycol, Propylene glycol, ethanol, and glycerin. 제4항에 있어서, 계면 활성제의 양이 약 0.5% 내지 약 5%인 제약 조성물.The pharmaceutical composition of claim 4, wherein the amount of surfactant is from about 0.5% to about 5%. 제5항에 있어서, 완충제가 아세트산염, 인산염 및 글루타민산염으로 이루어진 군으로부터선택된 것인 제약 조성물.6. The pharmaceutical composition of claim 5, wherein the buffer is selected from the group consisting of acetate, phosphate and glutamate. 제6항에 있어서, 완충제의 양이 약 0.005% 내지 약 0.5%인 제약 조성물.7. The pharmaceutical composition of claim 6, wherein the amount of buffer is from about 0.005% to about 0.5%. 제7항에 있어서, 제약상 허용되는 담체 및 희석제가 주사용 물 또는 명균수에 용해된 텍스트로즈 5%로 이우러진 군으로부터 선택된, 비경구 투여에 적합한 멸균 용액인 제약 조성물.8. A pharmaceutical composition according to claim 7, wherein the pharmaceutically acceptable carrier and diluent are sterile solutions suitable for parenteral administration, selected from the group consisting of 5% text rosin dissolved in injectable water or broth. 제1항에 있어서, 추가 완충제를 함유하는 제약 조성물.The pharmaceutical composition of claim 1, further comprising an additional buffer. 제9항에 있어서, 추가 완충제가 아세트산염, 인산 및 글루타민산염으로 이루어진 군으로부터 선택된 것인 제약 조성물.10. The pharmaceutical composition of claim 9, wherein the additional buffer is selected from the group consisting of acetate, phosphoric, and glutamate. 제1항에 있어서, 안전한 유효량의 공용매를 더 함유하는 제약 조성물.The pharmaceutical composition of claim 1, further comprising a safe effective amount of a co-solvent. 제11항에 있어서, 공용매가 폴리에틸렌 글리콜, 프로필렌 글리콜(1,2-프로판디올), 에탄올 및 글리세린으로 이루진 군으로부터 선택된 것인 제약 조성물.12. The pharmaceutical composition according to claim 11, wherein the co-solvent is selected from the group consisting of polyethylene glycol, propylene glycol (1,2-propanediol), ethanol and glycerin. 제1항에 있어서, 안전한 유효량의 추가 약물을 더 함유하는 제약 조성물.The pharmaceutical composition of claim 1, further comprising a safe effective amount of an additional drug. 제13항에 있어서, 안전한 유효량의 추가 약물이 항구토제, 항생제, 항우울제, 항궤양 화합물, 진통제, 항콜린작용제 및 항바이러스제로 이루어진 군으로부터 선택된 것인 제약 조성물.14. The pharmaceutical composition according to claim 13, wherein the safely effective amount of the additional drug is selected from the group consisting of antiepileptics, antibiotics, antidepressants, antiulcer compounds, analgesics, anticholinergics and antiviral agents. 제14항에 있어서, 안전한 유효량의 추가 약물이 새로토닌 5-HT3수용체 길항제, 프로클로르페라진, 클로로프로마진, 페르페나진, 티에닐페라진, 트리플루프로마진, 드로페리돌, 메토글로프라미드, 트리메토벤자미드, 드로나비놀, 페르에르간, 나빌론 및 메틸프레디니손으로 이루어진 군으로부터 선택된 항구토제인 제약 조성물.15. The method of claim 14, wherein the safely effective amount of the additional drug is selected from the group consisting of a novel tonin 5-HT 3 receptor antagonist, prochlorperazine, chloropromazine, perphenazine, thienyl ferrazine, triple loopmargin, Wherein the pharmaceutical composition is a detersive agent selected from the group consisting of ropridimide, trimethobenzamide, dronabinol, perergen, navelone and methylprednisone. 제15항에 있어서, 안전한 유효량의 추가 약물이 세로토닌 5-HT3수용체의 길항제인 제약 조성물.The method of claim 15, wherein the pharmaceutical composition is a drug added to a safe an effective amount of a serotonin 5-HT 3 receptor antagonists. 안전한 유효량의 제1항에 따른 조성물을 투여하는 다약물 내성의 역전, 감소 또는 억제, 또는 종양에 대한 민감도의 증가 또는 회복 방법.A method of reversing, reducing or inhibiting multidrug resistance, administering a safe effective amount of a composition according to claim 1, or increasing or ameliorating sensitivity to a tumor. 제18항에 있어서, 조성물이 비경구 주사. 또는 비경구 주입으로 투여되는 방법.19. The composition of claim 18, wherein the composition is parenterally injected. Or parenteral injection. a)패키지 재료: 및 b) i) 안전한 치료 유효량의 N-{4-[2-(1,2,3,4-테트라히드로-6,7-디메톡시-2-이소퀴놀리닐)-에틸]-페닐}-9,10-디히드로-5-매톡시-9-옥소-4-아크리딘 카르복사미드 및 이것의 생리적으로 허용되는 염 및 용매화물; ii) 안전한 유효량의 계면 활성제; iii) 완충제; 및 iv) 제약상 허용되는 담체 및 희석제를 포함하며 주사 또는 주입시에 조성물의 활성 성분의 침전을 방지하거나 최소화하는, 포장물질에 담겨 있는 제약 조성물로 이루어진 제품.A pharmaceutical composition comprising: a) a package material comprising: i) a safe therapeutically effective amount of N- {4- [2- (1,2,3,4-tetrahydro-6,7-dimethoxy-2-isoquinolinyl) ] -Phenyl} -9,10-dihydro-5-methoxy-9-oxo-4-acridine carboxamide and physiologically acceptable salts and solvates thereof; ii) a safe effective amount of a surfactant; iii) buffering agents; And iv) a pharmaceutically acceptable carrier and diluent, wherein the composition comprises a pharmaceutical composition contained in a packaging material that prevents or minimizes precipitation of the active ingredient of the composition upon injection or injection. 제19항에 있어서, 제품 정보를 담고 있는 소책자를 더 포함하는 제품.20. The article of claim 19, further comprising a booklet containing product information. ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.※ Note: It is disclosed by the contents of the first application.
KR1019970702223A 1994-10-05 1995-10-04 N-4-[2-1234--67--2--]--910--5--9--4- gf120918a parenteral pharmaceutical compositions containing gf120918a KR970705997A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US31830894A 1994-10-05 1994-10-05
US08/318,308 1994-10-05
PCT/US1995/012952 WO1996011007A1 (en) 1994-10-05 1995-10-04 Parenteral pharmaceutical compositions containing gf120918a

Publications (1)

Publication Number Publication Date
KR970705997A true KR970705997A (en) 1997-11-03

Family

ID=23237614

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019970702223A KR970705997A (en) 1994-10-05 1995-10-04 N-4-[2-1234--67--2--]--910--5--9--4- gf120918a parenteral pharmaceutical compositions containing gf120918a

Country Status (12)

Country Link
EP (1) EP0784474A2 (en)
JP (1) JPH10507177A (en)
KR (1) KR970705997A (en)
AU (1) AU702519B2 (en)
BR (1) BR9509251A (en)
CA (1) CA2201628A1 (en)
CZ (1) CZ104197A3 (en)
HU (1) HUT77883A (en)
NZ (1) NZ295546A (en)
PL (1) PL319511A1 (en)
RU (1) RU2157687C2 (en)
WO (1) WO1996011007A1 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9708805D0 (en) 1997-05-01 1997-06-25 Smithkline Beecham Plc Compounds
GB9710612D0 (en) * 1997-05-23 1997-07-16 Glaxo Group Ltd Synthesis of acridine derivatives
GB9810876D0 (en) 1998-05-20 1998-07-22 Smithkline Beecham Plc Compounds
US5922754A (en) * 1998-10-02 1999-07-13 Abbott Laboratories Pharmaceutical compositions containing paclitaxel
EA200100428A1 (en) 1998-10-08 2001-10-22 Смитклайн Бичам Плс TETRAHYDROBENZAZEPIN DERIVATIVES USEFUL AS A MODULATOR OF DOPAMINE D3 RECEPTORS (ANTIPSYHOTIC AGENTS)
AT408186B (en) * 1998-12-15 2001-09-25 Sanochemia Pharmazeutika Ag AQUEOUS PREPARATION OF BETA CAROTINE
ES2270834T3 (en) 1999-05-17 2007-04-16 Cancer Research Ventures Limited COMPOSITIONS TO IMPROVE THE BIODISPONIBILITY OF ORALLY MANAGED DRUGS.
US6521635B1 (en) 2000-01-20 2003-02-18 The United States Of America As Represented By The Department Of Health And Human Services Inhibition of MXR transport by acridine derivatives
ATE309786T1 (en) * 2000-06-30 2005-12-15 Inex Pharmaceuticals Corp LIPOSOMAL ANTINEOPLASTIC DRUGS AND USES THEREOF
WO2003002150A1 (en) * 2001-06-28 2003-01-09 Wyeth Composition and method for reducing adverse interactions between phenothiazine derivatives and plasma
KR100866728B1 (en) * 2004-11-12 2008-11-03 주식회사종근당 The injection of tacrolimus
FR2948568B1 (en) * 2009-07-30 2012-08-24 Sanofi Aventis PHARMACEUTICAL FORMULATION

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0494623A1 (en) * 1991-01-11 1992-07-15 Laboratoires Glaxo Sa Acridine derivatives

Also Published As

Publication number Publication date
HUT77883A (en) 1998-09-28
MX9702473A (en) 1997-07-31
RU2157687C2 (en) 2000-10-20
CA2201628A1 (en) 1996-04-18
CZ104197A3 (en) 1997-09-17
PL319511A1 (en) 1997-08-18
AU702519B2 (en) 1999-02-25
JPH10507177A (en) 1998-07-14
WO1996011007A1 (en) 1996-04-18
BR9509251A (en) 1997-10-21
AU3891395A (en) 1996-05-02
EP0784474A2 (en) 1997-07-23
NZ295546A (en) 1999-01-28

Similar Documents

Publication Publication Date Title
US5725878A (en) Pharmaceutical composition comprising HIV protease inhibiting compounds
JP5348818B2 (en) Stable high concentration meloxicam solution for needleless injection
KR970705997A (en) N-4-[2-1234--67--2--]--910--5--9--4- gf120918a parenteral pharmaceutical compositions containing gf120918a
PL318560A1 (en) Novel orally administered preparations containing cyclosporin of simple composition and high bioavailability
PL351259A1 (en) Composition containing testosterone undexanate and castor oil
BG106439A (en) Pharmaceutical composition of improved solubility and oral absorptivity, containing benzamide derivative
ATE331517T1 (en) PHARMACEUTICAL COMPOSITIONS
JP2005002123A5 (en)
GB9907715D0 (en) Pharmaceutical compositions
KR20000068528A (en) Stable Medicinal Compositions Containing 4,5-Epoxymorphinane Derivatives
WO2009111057A4 (en) Fulvestrant formulations
KR970032859A (en) Taxane composition and preparation method thereof
DE69734017D1 (en) DRUG COMPOSITIONS AND DEVICES FOR THEIR ADMINISTRATION
KR970706021A (en) A medicinal compounding agent consisting of N-substituted-o-toluidine derivatives, and a percutaneously absorbable broth agent (hereinafter, referred to as " medicinal preparations ", " medicinal preparations for oral administration "
RU2001129362A (en) COMPOSITION INCLUDING UNDECANOATE TESTOSTERONE AND CASTOR BUTTER
AU708688B2 (en) Composition comprising mupirocin and chlorhexidine
RU97107466A (en) PHARMACEUTICAL COMPOSITIONS FOR Parenteral Administration Containing GF120918A
EA200100871A1 (en) CRYSTALLINE FORM OF EUPLENONON, OWNED WITH INCREASED DISSOLUTION SPEED
CO5080752A1 (en) NF-kB TRANSCRIPTION FACTOR INHIBITORS
US5886018A (en) Pharmaceutical composition for parenteral administration containing an indole-carboxylic acid
MXPA04000535A (en) Antihistamine formulations for soft capsule dosage forms.
EP0867181A1 (en) Nasal melatonin composition
KR890014109A (en) Medication
US4760059A (en) Rectal dosage form
AU3941400A (en) Pharmaceutical composition

Legal Events

Date Code Title Description
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid